ArticleBiomedicines2022

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study.

Jose M Huguet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.